注射用头孢他啶阿维巴坦钠在肾移植患者术后获得性肺炎治疗中的价值分析

Analysis of the Value of Ceftazidime Avibactam Sodium for Injection in the Treatment of Postoperative Acquired Pneumonia in Renal Transplant Patients

目的:针对注射用头孢他啶阿维巴坦钠治疗肾移植患者术后获得性肺炎的临床应用价值进行分析研究,为临床提供有效依据。方法:选取2018年3月—2020年9月郑州市第七人民医院行肾移植手术后获得性肺炎的62例患者作为研究对象,采用随机数表法分为观察组与对照组,每组各31例,分别给予注射用头孢他啶阿维巴坦钠和注射用头孢呋辛钠进行为期2周的治疗,分析比较不同疗法下患者的肺炎治疗效果以及出现不良反应等情况。结果:经2周治疗后,观察组患者治疗有效率达93.55%,较之于对照组患者的74.19%有明显提高,差异有统计学意义(χ^(2)=4.292,P<0.05);与对照组患者相比,观察组患者咳嗽、发热、肺部干湿啰音等临床症状好转时间以及白细胞指标恢复时间均明显缩短,差异有统计学意义(t=-3.173、-2.351、-3.683、-2.873,P<0.05);观察组患者的致病菌有94.00%被清除,显著高于对照组患者的66.00%,差异有统计学意义(χ^(2)=5.872,P<0.05);两组患者治疗不良反应发生情况进行比较,差异无统计学意义(χ^(2)=0.350,P>0.05)。结论:注射用头孢他啶阿维巴坦钠在肾移植患者术后获得性肺炎治疗中疗效确切,能明显改善患者症状,具有较大临床应用价值。

Objective:To analyze and study the clinical application value of ceftazidime avibactam sodium for injection in the treatment of postoperative acquired pneumonia in renal transplant patients to provide an effective basis for clinical effectiveness.Methods:62 patients with acquired pneumonia after renal transplantation in hospitals from March 2018 to September 2020 were selected as study subjects,and were divided into observation group and control group using the random number table method,with 31 cases in each group.Ceftazidime avibactam sodium for injection and cefuroxime sodium for injection were given for a period of 2 weeks,respectively.The results of pneumonia treatment and the occurrence of adverse effects were analyzed and compared be⁃tween the different treatments.Results:After 2 weeks of treatment,the treatment efficiency of the observation group was 93.55%,which was higher than 74.19%of the control group,and the difference was statistically significant(χ^(2)=4.292,P<0.05).Compared with the control group,clinical symptoms such as cough,fever,dry and wet lung rales,and recovery time of leukocyte indexes were significantly shorter in the observation group,and the difference was statistically significant(t=-3.173,-2.351,-3.683,-2.873,P<0.05).In the observation group,94.00%of the pathogenic bacteria were cleared,which was significantly higher than 66.00%in the control group,with a statistically significant difference(χ^(2)=5.872,P<0.05).There was no statistically significant difference in the occurrence of adverse reactions to treatment between the two groups(χ^(2)=0.350,P>0.05).Conclusion:Ceftazidime avibactam sodium for injection is effective in the treatment of postoperative acquired pneumonia in renal transplant patients,which can significantly improve patients’symptoms and has greater clinical application value.